Liquidia Corporation to Report Full Year 2022 Financial Results on Thursday, March 16, 2023

Rhea-AI Summary

Liquidia Corporation (NASDAQ: LQDA) will announce its full-year 2022 financial results on March 16, 2023. A live webcast is scheduled for 8:30 a.m. Eastern Time, where the company will discuss its financial outcomes and provide a corporate update.

Liquidia is a biopharmaceutical firm focusing on pulmonary hypertension treatments, utilizing its PRINT® Technology. Its YUTREPIA™ inhalation powder has received tentative FDA approval for pulmonary arterial hypertension (PAH), indicating progress in its product development.

Positive

• Tentative FDA approval for YUTREPIA™ inhalation powder for PAH treatment.

Negative

• None.

News Market Reaction – LQDA

-5.41%

-5.41% Session move

In the trading session that priced this news, LQDA declined 5.41%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MORRISVILLE, N.C., March 09, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2022 financial results on Thursday, March 16, 2023. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update.

The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of 30 days at the same location.

About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT^® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder, which has received tentative approval from the FDA for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH provides the commercialization for pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection. For more information, please visit www.liquidia.com.

Contact Information

Media & Investors:
Jason Adair
Senior Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com

FAQ

When will Liquidia Corporation report its 2022 financial results?

Liquidia Corporation will report its full-year 2022 financial results on March 16, 2023.

What time is the Liquidia Corporation webcast on March 16, 2023?

The webcast will start at 8:30 a.m. Eastern Time on March 16, 2023.

What product has Liquidia received FDA tentative approval for?

Liquidia has received tentative FDA approval for YUTREPIA™ inhalation powder for treating pulmonary arterial hypertension.

Where can I access the Liquidia Corporation webcast?

The webcast will be available on Liquidia's website and archived for 30 days.